| Lori Shah, MD | |
|
622 W 168th St, Columbia Department Of Medicine, New York, NY 10032-3720 | |
| (212) 305-9819 | |
| (212) 305-8464 |
| Full Name | Lori Shah |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 26 Years |
| Location | 622 W 168th St, New York, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043239163 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 215039 (New York) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 215039 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York-presbyterian Hospital | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trustees Of Columbia University In The City Of New York | 8527972546 | 1895 |
News Archive
A new clinical prediction index has been developed to determine the risk of death in patients with end-stage kidney disease considering transplantation, states a Research article in CMAJ.
Trimetazidine administered after successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, according to results of the ATPCI trial presented in a Hot Line session today at ESC Congress 2020.
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
Our ancestors evolutionarily split from those of rhesus monkeys about 25 million years ago. Since then, brain areas have been added, have disappeared or have changed in function. This raises the question, 'Has evolution given humans unique brain structures?'. Scientists have entertained the idea before but conclusive evidence was lacking. By combining different research methods, we now have a first piece of evidence that could prove that humans have unique cortical brain networks.
› Verified 5 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437176047 PECOS PAC ID: 6002715794 Enrollment ID: O20031231000637 |
News Archive
A new clinical prediction index has been developed to determine the risk of death in patients with end-stage kidney disease considering transplantation, states a Research article in CMAJ.
Trimetazidine administered after successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, according to results of the ATPCI trial presented in a Hot Line session today at ESC Congress 2020.
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
Our ancestors evolutionarily split from those of rhesus monkeys about 25 million years ago. Since then, brain areas have been added, have disappeared or have changed in function. This raises the question, 'Has evolution given humans unique brain structures?'. Scientists have entertained the idea before but conclusive evidence was lacking. By combining different research methods, we now have a first piece of evidence that could prove that humans have unique cortical brain networks.
› Verified 5 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982993184 PECOS PAC ID: 8527972546 Enrollment ID: O20040407001360 |
News Archive
A new clinical prediction index has been developed to determine the risk of death in patients with end-stage kidney disease considering transplantation, states a Research article in CMAJ.
Trimetazidine administered after successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, according to results of the ATPCI trial presented in a Hot Line session today at ESC Congress 2020.
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
Our ancestors evolutionarily split from those of rhesus monkeys about 25 million years ago. Since then, brain areas have been added, have disappeared or have changed in function. This raises the question, 'Has evolution given humans unique brain structures?'. Scientists have entertained the idea before but conclusive evidence was lacking. By combining different research methods, we now have a first piece of evidence that could prove that humans have unique cortical brain networks.
› Verified 5 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508266347 PECOS PAC ID: 8527972546 Enrollment ID: O20151201002613 |
News Archive
A new clinical prediction index has been developed to determine the risk of death in patients with end-stage kidney disease considering transplantation, states a Research article in CMAJ.
Trimetazidine administered after successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, according to results of the ATPCI trial presented in a Hot Line session today at ESC Congress 2020.
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
Our ancestors evolutionarily split from those of rhesus monkeys about 25 million years ago. Since then, brain areas have been added, have disappeared or have changed in function. This raises the question, 'Has evolution given humans unique brain structures?'. Scientists have entertained the idea before but conclusive evidence was lacking. By combining different research methods, we now have a first piece of evidence that could prove that humans have unique cortical brain networks.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lori Shah, MD 622 W 168th St, Columbia Department Of Medicine, New York, NY 10032-3720 Ph: (212) 305-9819 | Lori Shah, MD 622 W 168th St, Columbia Department Of Medicine, New York, NY 10032-3720 Ph: (212) 305-9819 |
News Archive
A new clinical prediction index has been developed to determine the risk of death in patients with end-stage kidney disease considering transplantation, states a Research article in CMAJ.
Trimetazidine administered after successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, according to results of the ATPCI trial presented in a Hot Line session today at ESC Congress 2020.
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.
Our ancestors evolutionarily split from those of rhesus monkeys about 25 million years ago. Since then, brain areas have been added, have disappeared or have changed in function. This raises the question, 'Has evolution given humans unique brain structures?'. Scientists have entertained the idea before but conclusive evidence was lacking. By combining different research methods, we now have a first piece of evidence that could prove that humans have unique cortical brain networks.
› Verified 5 days ago
Dr. Ravishankar Ramaswamy, MD, MS Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1440 Madison Avenue, New York, NY 10029 Phone: 212-659-8552 Fax: 212-860-9737 | |
Dr. Pietro Alessandro Ambrogio Canetta, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, Ph4-124, New York, NY 10032 Phone: 212-305-5020 Fax: 212-305-6692 | |
Dr. Rakhshan Mahmood Chida, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 327 E 17th St, New York, NY 10003 Phone: 212-420-5690 | |
Charles D Resor, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, New York, NY 10032 Phone: 212-305-2913 | |
Dr. Jacqueline Yuey Lonier, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1150 Saint Nicholas Ave, New York, NY 10032 Phone: 212-851-5494 | |
Dr. Sharon Uralil, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 550 1st Ave, New York, NY 10016 Phone: 212-263-3293 | |
Diana Kantor, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 775 9th Ave, New York, NY 10019 Phone: 212-586-1550 |